Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's Avastin Labeling Adds Warning On Thromboembolic Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Updated labeling includes warning on arterial thromboembolic events described in August "Dear Healthcare Provider" letter. Patients treated with Avastin plus chemotherapy had a 4.4% incidence of thromboembolic events versus 1.9% in patients on chemotherapy alone.
Advertisement

Related Content

Genentech's Avastin Gaining Market Share In On- And Off-Label Indications
Genentech's Avastin Gaining Market Share In On- And Off-Label Indications
Avastin Labeling Will Reflect New Data On Thromboembolic Events
Avastin Labeling Will Reflect New Data On Thromboembolic Events
Genentech Avastin Approved For Colorectal Cancer With Five-Month Survival Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS061050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel